クリングルファーマ(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証GRT | 医薬品 | 4884/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2024/04/26 | 日証協 | 613,000株 | -2.68% | 70,200株 | -47.18% | 801,036株 | -1.89% | 27,500株 | -25.55% |
2024/04/19 | 日証協 | 629,900株 | +1.47% | 132,900株 | +47.34% | 816,429株 | +1.9% | 36,939株 | -33.34% |
2024/04/12 | 日証協 | 620,800株 | +4.74% | 90,200株 | +7.64% | 801,209株 | +2.72% | 55,410株 | +29.16% |
2024/04/05 | 日証協 | 592,700株 | +3.78% | 83,800株 | -21.17% | 779,999株 | +4.33% | 42,900株 | -64.72% |
2024/03/29 | 日証協 | 571,100株 | +15.61% | 106,300株 | +60.82% | 747,598株 | +5.1% | 121,602株 | +35.11% |
2024/03/22 | 日証協 | 494,000株 | -9.04% | 66,100株 | -5.03% | 711,298株 | -2.08% | 90,000株 | +87.5% |
2024/03/15 | 日証協 | 543,100株 | +10.07% | 69,600株 | -30.47% | 726,398株 | +5.94% | 48,000株 | -41.03% |
2024/03/08 | 日証協 | 493,400株 | +17.48% | 100,100株 | +58.89% | 685,698株 | +7.48% | 81,400株 | +34.1% |
2024/03/01 | 日証協 | 420,000株 | +8.3% | 63,000株 | +85.29% | 637,998株 | +6.32% | 60,700株 | +30.82% |
2024/02/22 | 日証協 | 387,800株 | +5.18% | 34,000株 | -47.93% | 600,098株 | -13.44% | 46,400株 | -77.73% |
2024/02/16 | 日証協 | 368,700株 | +5.52% | 65,300株 | +256.83% | 693,288株 | +19.25% | 208,310株 | +760.79% |
2024/02/09 | 日証協 | 349,400株 | -11.72% | 18,300株 | -72.4% | 581,388株 | -15.46% | 24,200株 | -84.34% |
2024/02/02 | 日証協 | 395,800株 | +4.1% | 66,300株 | +41.97% | 687,688株 | +15.52% | 154,500株 | +376.85% |
2024/01/26 | 日証協 | 380,200株 | +0.16% | 46,700株 | -29.14% | 595,288株 | +0.4% | 32,400株 | -51.64% |
2024/01/19 | 日証協 | 379,600株 | -12.76% | 65,900株 | +191.59% | 592,888株 | -9.78% | 67,000株 | +352.7% |
2024/01/12 | 日証協 | 435,100株 | -1.23% | 22,600株 | -60.21% | 657,189株 | -1.16% | 14,800株 | -26.37% |
2024/01/05 | 日証協 | 440,500株 | +0.52% | 56,800株 | -20.67% | 664,889株 | +0.35% | 20,100株 | -85.24% |
2023/12/29 | 日証協 | 438,200株 | -13.55% | 71,600株 | -45.51% | 662,589株 | -14.25% | 136,202株 | +65.09% |
2023/12/22 | 日証協 | 506,900株 | -0.04% | 131,400株 | -5.74% | 772,689株 | +2.03% | 82,500株 | -54.01% |
※株式分割は考慮していませんのでご注意ください。
Page Top